CORRESP Filing
Aprea Therapeutics, Inc.
Date: April 27, 2026 · CIK: 0001781983 · Accession: 0001104659-26-049298
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-295247
Letter
APREA THERAPEUTICS, INC.
3805 Old Easton Road
Doylestown, PA 18902
April 27, 2026
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attention: Doris Stacey Gama
Re: Aprea Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-295247
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295247), so that it may become effective at 5:00 p.m. Eastern Time on April 29, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement.
Very truly yours,
APREA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm APREA THERAPEUTICS, INC. 3805 Old Easton Road Doylestown, PA 18902 April 27, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Aprea Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-295247 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295247), so that it may become effective at 5:00 p.m. Eastern Time on April 29, 2026, or as soon as practicable thereafter, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions regarding the Registration Statement. Very truly yours, APREA THERAPEUTICS, INC. By: /s/ Oren Gilad Name: Oren Gilad Title: Chief Executive Officer cc: Fahd Riaz, Esq., DLA Piper LLP (US) Dylan Caplan, Esq., DLA Piper LLP (US)